Astellas Pharma Gmbh

Kazuyuki Kuramoto

Ryo Sato

Eiji Kawaminami

Tomoyoshi Imaizumi

Hiroyuki Kaizawa

Takeyuki Nagashima

Takanori Koike

Ryushi Seo

Susumu Yamaki

Itsuro Shimada

Kazuhiko Take

Kazuyuki Sakamoto

Hisao Hamaguchi

Kazushi Watanabe

Takatoshi Kanayama

Tomoaki Abe

Yuta Fukuda

Takahiro Nigawara

Yutaka Kondoh

Tatsuhisa Takahashi

Shigeki Kunikawa

Keisuke Arakawa

Michinori Akaiwa

Takanobu Araki

Yoshiki Satake

Yuki Sawada

Takahiro Morikawa

Tomoyuki Saito

Kenichi Kawaguchi

Hidenori Azami

Sunao Imada

Yohei Seki

Kei Ohnuki

Ikumi Kuriwaki

Takashi Shin

Mitsuaki Okumura

Hiroki Fukudome

Masashi Shimazaki

Kohei Inamura

Hideyuki Watanabe

Hiroki Ishioka

Shigetoshi Kikuchi

Tomohiro Yoshinari

[Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. [Means for resolution] The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a quinazoline compound has an excellent degradation-inducing action on a G12D mutant KRAS protein and a G12D mutant KRAS inhibition activity and can be used as a therapeutic agent for pancreatic cancer, thus completing the present invention. The quinazoline compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.

Quinazoline compound for inducing degradation of G12D mutant KRAS protein

[Problem] Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer. [Means for Solution] The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer.

Quinazoline compound

Compounds of formula (I) and salts thereof: wherein the variables are defined herein, are useful for the treatment of breast cancer.

Bicyclic nitrogen-containing aromatic heterocyclic amide compound

A substituted amide compound is useful as an active ingredient of a pharmaceutical composition, in particular a pharmaceutical composition for treating diseases caused by lysophosphatidic acid (LPA). The compound is of a formula:  In this formula, A is an optionally substituted aryl, etc.; B is an optionally substituted 5-membered aromatic hetero ring group; X is a single bond or &#x2014;(CRR)&#x2014;; n is 1, 2, 3, or 4; Rand Rare hydrogen, etc.; Yto Yare each CRor N; each Ris hydrogen, etc.; Rand Rare hydrogen, etc.; m is 1, 2, or 3; Ris hydrogen, etc.; and Ris an optically substituted lower alkyl, etc.

Substituted amide compound

A substituted amide compound is useful as an active ingredient of a pharmaceutical composition, in particular a pharmaceutical composition for treating diseases caused by lysophosphatidic acid (LPA). The compound is of a formula: In this formula, A is an optionally substituted aryl, etc.; B is an optionally substituted 5-membered aromatic hetero ring group; X is a single bond or &#x2014;(CRR)&#x2014;; n is 1, 2, 3, or 4; Rand Rare hydrogen, etc.; Yto Yare each CRor N; each Ris hydrogen, etc.; Rand Rare hydrogen, etc.; m is 1, 2, or 3; Ris hydrogen, etc.; and Ris an optionally substituted lower alkyl, etc.

Growing community of inventors

Tokyo, Japan

Kazuyuki Kuramoto